Benjamin Lallemant

Benjamin Lallemant

Auto-generated profile, based on publicly available information

Benjamin Lallemant

Institut National de la Santé et de la Recherche Médicale, U661 Montpellier F-34094, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
CRCaroline Raynal
Caroline Raynal
JPJean-Marc Pascussi
Jean-Marc Pascussi
GLGéraldine Leguelinel
Géraldine Leguelinel
CBCyril Breuker
Cyril Breuker
JKJovana Kantar
Jovana Kantar
AEAlexandre Evrard
Alexandre Evrard
Background: Clinical efficacy of chemotherapy in colorectal cancer is subjected to broad inter-individual variations leading to the inability to predict outcome and toxicity. The topoisomerase I inhibitor irinotecan (CPT-11) is worldwide approved for the treatment of metastatic colorectal cancer and undergoes extensive peripheral and tumoral metabolism. PXR is a xenoreceptor activated by many drugs and environmental compounds regulating the expression of drug metabolism and transport genes in detoxification organs such as liver and gastrointestinal tract. Considering the metabolic pathway of irinotecan and the tissue distribution of Pregnane × Receptor (PXR), we hypothesized that PXR could play a key role in colon cancer cell response to irinotecan.Results: PXR mRNA expression was quantified by RT-quantitative PCR in a panel of 14 colon tumor samples and their matched normal tissues. PXR expression was modulated in human colorectal cancer cells LS174T, SW480 and SW620 by transfection and siRNA strategies. Cellular response to irinotecan and its active metabolic SN38 was assessed by cell viability assays, HPLC metabolic profiles and mRNA quantification of PXR target genes. We showed that PXR was strongly expressed in colon tumor samples and displayed a great variability of expression. Expression of hPXR in human colorectal cancer cells led to a marked chemoresistance to the active metabolite SN38 correlated with PXR expression level. Metabolic profiles of SN38 showed a strong enhancement of SN38 glucuronidation to the inactive SN38G metabolite in PXR-expressing cells, correlated with an increase of UDPglucuronosyl transferases UGT1A1, UGT1A9 and UGT1A10 mRNAs. Inhibition of PXR expression by lentivirus-mediated shRNA, led to SN38 chemoresistance reversion concomitantly to a decrease of UGT1A1 expression and SN38 glucuronidation. Similarly, PXR mRNA expression levels correlated to UGT1A subfamily expression in human colon tumor biopsies.Conclusion: Our results demonstrate that tumoral metabolism of SN38 is affected by PXR and point to potential therapeutic significance of PXR quantification in the prediction of irinotecan response. Furthermore, our observations are pharmacologically relevant since many patients suffering from cancer diseases are often exposed to co-medications, food additives or herbal supplements able to activate PXR. A substantial part of the variability observed among patients might be caused by such interactions

5 August 2013 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
BLBenjamin Lallemant
Benjamin Lallemant
GCGuillaume Chambon
Guillaume Chambon
RGRenaud Garrel
Renaud Garrel
SKSophie Kacha
Sophie Kacha
DRDamien Rupp
Damien Rupp
HPHuy Trang Pham
Huy Trang Pham

1 June 2021 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
MBMarie De Boutray
Marie De Boutray
JDJean-Daniel Kun Darbois
Jean-Daniel Kun Darbois
NSN. Sigaux
N. Sigaux
JLJean-Christophe LUTZ
Jean-Christophe LUTZ
AVA. Veyssiere
A. Veyssiere
JFJean-Marc Foletti
Jean-Marc Foletti

18 October 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BLBenjamin Lallemant
Benjamin Lallemant
AEAlexandre Evrard
Alexandre Evrard
CCChristophe Combescure
Christophe Combescure
HCHeliette Chapuis
Heliette Chapuis
GCGuillaume Chambon
Guillaume Chambon
JBJean-Paul Brouillet
Jean-Paul Brouillet
Analysis of 23 published transcriptome studies allowed us to identify nine genes displaying frequent alterations in HNSCC (FN1, MMP1, PLAU, SPARC, IL1RN, KRT4, KRT13, MAL, and TGM3). We aimed to independently confirm these dysregulations and to identify potential relationships with clinical data for diagnostic, staging and prognostic purposes either at the tissue level or in saliva rinse.

1 January 2009 in BMC Molecular Biology
Verified
Journal Article
Open access
PDF file
BLBenjamin Lallemant
Benjamin Lallemant
AEAlexandre Evrard
Alexandre Evrard
CCChristophe Combescure
Christophe Combescure
HCHeliette Chapuis
Heliette Chapuis
GCGuillaume Chambon
Guillaume Chambon
JBJean-Paul Brouillet
Jean-Paul Brouillet
It is no longer adequate to choose reference genes blindly. We present the first study that defines the suitability of 12 reference genes commonly used in cancer studies (ACT, ALAS, B2M, GAPDH, HMBS, HPRT, KALPHA, RPS18, RPL27, RPS29, SHAD and TBP) for the normalization of quantitative expression data in the field of head and neck squamous cell carcinoma (HNSCC).

14 October 2010 in Head & Neck
Verified
Journal Article
Closed access
PDF file
BLBenjamin Lallemant
Benjamin Lallemant
AEAlexandre Evrard
Alexandre Evrard
GCGuillaume Chambon
Guillaume Chambon
OSOmar Sabra
Omar Sabra
SKSophie Kacha
Sophie Kacha
JBJean‐Paul Brouillet
Jean‐Paul Brouillet